Skip to main content
. Author manuscript; available in PMC: 2011 Apr 19.
Published in final edited form as: Vaccine. 2010 Mar 1;28(18):3219–3230. doi: 10.1016/j.vaccine.2010.02.022

Fig. 2.

Fig. 2

Antibody responses in sera and fecal extracts to F1- and V-Ags. BALB/c (10/group) were first dosed with DNA vaccines (A,B) nasally or (C,D) intramuscularly on wks 0, 1, and 2 followed by nasal boosts with recombinant F1-Ag plus 2.5 μg CT on wks 8 and 9. A kinetic analysis was performed using the LTN/V DNA and LTN/F1-V DNA vaccines. Serum IgG and fecal IgA Ab titers to F1- and V-Ags were followed for 12 wks. Data depict the mean ± SD.